ProKidney maintains cash runway to 2027 despite wider quarterly loss
Biotech's Phase 3 kidney disease trial on track as FDA aligns on accelerated approval pathway
ProKidney shares were largely unchanged on Wednesday after the biotechnology company reported a wider-than-expected annual loss, though investors focused on the company's substantial cash position and progress in its pivotal clinical trial program.
The North Carolina-based company reported full-year 2025 results showing a net loss of $151.6 million, or $0.52 per share, compared with analyst expectations of a $0.14 per share loss. Revenue totaled just $900,000, reflecting the company's pre-revenue stage as it advances its experimental treatment for chronic kidney disease through late-stage clinical testing.
Despite the earnings miss, ProKidney's stock showed little reaction, trading at $2.08, down 2.4% on the day. The muted response underscores how investors in clinical-stage biotechnology companies prioritize cash runway and clinical trial progress over near-term financial metrics.
ProKidney ended 2025 with $270 million in cash and marketable securities, down from $358.3 million at the end of 2024. The company said this capital position provides sufficient funding to support operations into mid-2027, a critical timeframe that encompasses the anticipated data readout from its Phase 3 PROACT 1 trial of rilparencel.
"We enter 2026 with a strong balance sheet and clear line of sight to our pivotal data readout," the company stated in its earnings release. ProKidney's research and development expenses declined to $114.1 million in 2025 from $127.7 million the previous year, as the company completed certain earlier-stage trials while advancing its flagship Phase 3 program.
The company's most significant development came in July 2025, when it achieved alignment with the U.S. Food and Drug Administration on an accelerated approval pathway for rilparencel, using estimated glomerular filtration rate (eGFR) slope as a surrogate endpoint. The FDA confirmed that the PROACT 1 study could support both accelerated and traditional approval submissions, potentially streamlining the regulatory timeline.
ProKidney is now on track to complete patient enrollment for the accelerated approval efficacy analysis portion of the Phase 3 trial by mid-2026, with approximately 360 patients. Full enrollment for the confirmatory analysis, targeting about 470 patients, is expected in the second half of 2026. Pivotal topline results based on the eGFR slope endpoint are anticipated in the second quarter of 2027, followed by Biologics License Application submission in the fourth quarter of that year.
The company estimates potential regulatory approval and commercial launch could occur in the second half of 2028, with confirmatory data supporting full approval expected in the second half of 2029. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, a status intended to expedite development and review for promising treatments.
Wall Street sentiment toward ProKidney remains divided. Analysts maintain an average price target of $6.25, representing substantial upside from current levels, though the consensus rating is a "Hold" based on four buy recommendations, two holds, and one strong sell. H.C. Wainwright has maintained a buy rating with a $12 price target, reflecting the significant commercial opportunity if the Phase 3 trial succeeds.
Chronic kidney disease affects more than 850 million people worldwide, with diabetic kidney disease representing a major subset. ProKidney's rilparencel is designed as an autologous cell therapy that targets patients with advanced chronic kidney disease and diabetes who are at high risk of kidney failure. The treatment aims to preserve kidney function and potentially delay or prevent the need for dialysis or transplantation.
The company also reported positive results from its Phase 2 REGEN-007 study of rilparencel, which were presented at ASN Kidney Week 2025 as a late-breaking clinical trial and subsequently published in the Clinical Journal of the American Society of Nephrology. Additionally, ProKidney has initiated expansion of its manufacturing facilities, adding 180,000 square feet across two company-owned sites in Winston-Salem to support potential commercial production.
With shares trading near their 50-day moving average of $2.18 and well below their 52-week high of $5.95, ProKidney presents a classic binary investment scenario characteristic of late-stage biotechnology companies. Success in the Phase 3 trial could unlock significant value given the large unmet medical need in chronic kidney disease, while clinical setbacks or regulatory delays would pressure the stock given the company's pre-revenue status.